SLC2A1 and Hypoglycemia: Recently, LAC infusions have been successfully employed to treat patients with hypoglycemia, TBI and Alzheimer’s, suggesting that GLUT1-DS patients resistant to the KD might also benefit from this treatment [77] (van Gemert et al., 2022).